These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 18334747)

  • 1. Generation, characterization and biological activity of CCL2 (MCP-1/JE) and CCL12 (MCP-5) specific antibodies.
    Tsui P; Das A; Whitaker B; Tornetta M; Stowell N; Kesavan P; Kaiser E; Lacy ER; Yan L; Snyder LA; Sweet R
    Hum Antibodies; 2007; 16(3-4):117-25. PubMed ID: 18334747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cloning and functional characterization of the rabbit C-C chemokine receptor 2.
    Lu D; Yuan XJ; Evans RJ; Pappas AT; Wang H; Su EW; Hamdouchi C; Venkataraman C
    BMC Immunol; 2005 Jul; 6():15. PubMed ID: 16001983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential involvement of monocyte chemoattractant protein (MCP)-1/CCL2 in IL-4-mediated tumor immunity through inducing dendritic cell migration into the draining lymph nodes.
    Wang H; Nemoto-Sasaki Y; Kondo T; Akiyama M; Mukaida N
    Int Immunopharmacol; 2003 May; 3(5):627-42. PubMed ID: 12757733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological characterization of human monocyte chemoattractant protein 1 (MCP-1) and its analogs.
    Kruszynski M; Stowell N; Das A; Seideman J; Tsui P; Brigham-Burke M; Nemeth JF; Sweet R; Heavner GA
    J Pept Sci; 2006 Jan; 12(1):25-32. PubMed ID: 15942931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological profile of JNJ-27141491 [(S)-3-[3,4-difluorophenyl)-propyl]-5-isoxazol-5-yl-2-thioxo-2,3-dihydro-1H-imidazole-4-carboxyl acid methyl ester], as a noncompetitive and orally active antagonist of the human chemokine receptor CCR2.
    Buntinx M; Hermans B; Goossens J; Moechars D; Gilissen RA; Doyon J; Boeckx S; Coesemans E; Van Lommen G; Van Wauwe JP
    J Pharmacol Exp Ther; 2008 Oct; 327(1):1-9. PubMed ID: 18599682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure activity relationships of monocyte chemoattractant proteins in complex with a blocking antibody.
    Reid C; Rushe M; Jarpe M; van Vlijmen H; Dolinski B; Qian F; Cachero TG; Cuervo H; Yanachkova M; Nwankwo C; Wang X; Etienne N; Garber E; Bailly V; de Fougerolles A; Boriack-Sjodin PA
    Protein Eng Des Sel; 2006 Jul; 19(7):317-24. PubMed ID: 16682434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production and in vivo effects of chemokines CXCL1-3/KC and CCL2/JE in a model of inflammatory angiogenesis in mice.
    Barcelos LS; Talvani A; Teixeira AS; Cassali GD; Andrade SP; Teixeira MM
    Inflamm Res; 2004 Oct; 53(10):576-84. PubMed ID: 15597153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking mast cell-mediated type I hypersensitivity in experimental allergic conjunctivitis by monocyte chemoattractant protein-1/CCR2.
    Tominaga T; Miyazaki D; Sasaki S; Mihara S; Komatsu N; Yakura K; Inoue Y
    Invest Ophthalmol Vis Sci; 2009 Nov; 50(11):5181-8. PubMed ID: 19553621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic up-regulation of MCP-2/CCL8 activity is counteracted by chemokine cleavage, limiting its inflammatory and anti-tumoral effects.
    Struyf S; Proost P; Vandercappellen J; Dempe S; Noyens B; Nelissen S; Gouwy M; Locati M; Opdenakker G; Dinsart C; Van Damme J
    Eur J Immunol; 2009 Mar; 39(3):843-57. PubMed ID: 19224633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial impact of CCL2 and CCL12 neutralization on experimental malignant pleural effusion.
    Marazioti A; Kairi CA; Spella M; Giannou AD; Magkouta S; Giopanou I; Papaleonidopoulos V; Kalomenidis I; Snyder LA; Kardamakis D; Stathopoulos GT
    PLoS One; 2013; 8(8):e71207. PubMed ID: 23967166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanical analysis of tumor growth regression by the cyclooxygenase-2 inhibitor, DFU, in a Walker256 rat tumor model: importance of monocyte chemoattractant protein-1 modulation.
    Muta M; Matsumoto G; Nakashima E; Toi M
    Clin Cancer Res; 2006 Jan; 12(1):264-72. PubMed ID: 16397051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion.
    Stathopoulos GT; Psallidas I; Moustaki A; Moschos C; Kollintza A; Karabela S; Porfyridis I; Vassiliou S; Karatza M; Zhou Z; Joo M; Blackwell TS; Roussos C; Graf D; Kalomenidis I
    J Natl Cancer Inst; 2008 Oct; 100(20):1464-76. PubMed ID: 18840818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity: therapeutic opportunities and controversies.
    Daly C; Rollins BJ
    Microcirculation; 2003 Jun; 10(3-4):247-57. PubMed ID: 12851642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo.
    Loberg RD; Ying C; Craig M; Day LL; Sargent E; Neeley C; Wojno K; Snyder LA; Yan L; Pienta KJ
    Cancer Res; 2007 Oct; 67(19):9417-24. PubMed ID: 17909051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyper-responsiveness of IPF/UIP fibroblasts: interplay between TGFbeta1, IL-13 and CCL2.
    Murray LA; Argentieri RL; Farrell FX; Bracht M; Sheng H; Whitaker B; Beck H; Tsui P; Cochlin K; Evanoff HL; Hogaboam CM; Das AM
    Int J Biochem Cell Biol; 2008; 40(10):2174-82. PubMed ID: 18395486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice.
    Koga M; Kai H; Egami K; Murohara T; Ikeda A; Yasuoka S; Egashira K; Matsuishi T; Kai M; Kataoka Y; Kuwano M; Imaizumi T
    Biochem Biophys Res Commun; 2008 Jan; 365(2):279-84. PubMed ID: 17991428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic, site-specific biotinylated analogs of human MCP-1.
    Kruszynski M; Tsui P; Stowell N; Luo J; Nemeth JF; Das AM; Sweet R; Heavner GA
    J Pept Sci; 2006 May; 12(5):354-60. PubMed ID: 16285024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel recombinant fusion protein encoding a 20-amino acid residue of the third extracellular (E3) domain of CCR2 neutralizes the biological activity of CCL2.
    Izhak L; Wildbaum G; Zohar Y; Anunu R; Klapper L; Elkeles A; Seagal J; Yefenof E; Ayalon-Soffer M; Karin N
    J Immunol; 2009 Jul; 183(1):732-9. PubMed ID: 19535619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the angiogenesis by the MCP-1 (monocyte chemoattractant protein-1) binding peptide.
    Kim MY; Byeon CW; Hong KH; Han KH; Jeong S
    FEBS Lett; 2005 Mar; 579(7):1597-601. PubMed ID: 15757647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulation of CCL2 (MCP-1) and CCL2 mRNA by substance P in LAD2 human mast cells.
    Castellani ML; Vecchiet J; Salini V; Conti P; Theoharides TC; Caraffa A; Antinolfi P; Teté S; Ciampoli C; Cuccurullo C; Cerulli G; Felaco M; Boscolo P
    Transl Res; 2009 Jul; 154(1):27-33. PubMed ID: 19524871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.